Literature DB >> 27088710

Severe Sepsis and Septic Shock Associated with Chikungunya Virus Infection, Guadeloupe, 2014.

Amélie Rollé, Kinda Schepers, Sylvie Cassadou, Elodie Curlier, Benjamin Madeux, Cécile Hermann-Storck, Isabelle Fabre, Isabelle Lamaury, Benoit Tressières, Guillaume Thiery, Bruno Hoen.   

Abstract

During a 2014 outbreak, 450 patients with confirmed chikungunya virus infection were admitted to the University Hospital of Pointe-à-Pitre, Guadeloupe. Of these, 110 were nonpregnant adults; 42 had severe disease, and of those, 25 had severe sepsis or septic shock and 12 died. Severe sepsis may be a rare complication of chikungunya virus infection.

Entities:  

Keywords:  CHIKV; French West Indies; Guadeloupe; chikungunya; septic shock; severe sepsis; vector-borne infections; viruses

Mesh:

Year:  2016        PMID: 27088710      PMCID: PMC4861514          DOI: 10.3201/eid2205.151449

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


In November 2013, the first autochthonous cases of chikungunya virus (CHIKV) infection were identified in the territory of Saint-Martin in the French West Indies (). Since that time, local transmission of the virus has been identified in nearly all Caribbean islands and in Central and South America (). In Guadeloupe, an outbreak started in the first weeks of 2014 and ended by November 2014. No new definite case of chikungunya has been reported since January 2015. During the 2014 outbreak, ≈40% of the population (≈160,000 persons) became infected with CHIKV. However, the hospitalization rate for chikungunya was <0.5%. A total of 450 patients with CHIKV infection and a positive reverse transcription PCR (RT-PCR) test result for CHIKV were admitted to the University Hospital of Pointe-à-Pitre (UHPAP), Guadeloupe, and were hospitalized >24 hours. Of these 450 patients, 241 were children, 99 were pregnant women, and 110 were nonpregnant adults. The objectives of our study were 1) to describe the characteristics of nonpregnant adult patients who had atypical or severe forms of the disease and 2) to search for predictive factors for severe forms.

The Study

During the outbreak, a standardized case report form was filled out for each patient admitted to UHPAP who had clinical symptoms consistent with chikungunya and a positive CHIKV RT-PCR test result on a blood sample. The information recorded included demographics, preexisting comorbidities, which were summarized by using the Charlson index () and McCabe classification (), and clinical manifestations described by organ system (e.g., cardio-circulatory, cerebral, respiratory, renal, and hepatic). Standard definitions were used for organ system failures and severe sepsis and septic shock (). The following laboratory parameters were retrieved from the patient’s record in the hospital’s electronic medical system: whole and differential leukocyte and platelet counts; corpuscular hemoglobin; and C-reactive protein, serum creatinine, alanine aminotransferase, aspartate aminotransferase, creatine kinase, and lactate dehydrogenase levels. For each parameter, 2 values were considered, the first value recorded within the first 24 hours of admission and the most abnormal value observed from hospital day 2 through day 7. After hospital discharge or death, each case of CHIKV infection was categorized as one of the following: 1) a common form, in which only fever or arthralgia occurred; 2) an atypical form, in which >1 organ system was involved; and 3) a severe form, in which the patient had >1 organ system failure or had been admitted to the intensive care unit. Of the 110 nonpregnant adults hospitalized with chikungunya who had a positive CHIKV RT-PCR test result, 34 had a common form, 34 had an atypical form, and 42 had a severe form. Overall, the characteristics of patients with common and atypical forms were similar. Therefore, we compared the characteristics of the 48 patients with severe forms with those of the 68 patients with nonsevere forms (i.e., common and atypical forms) by selected demographic, clinical, laboratory, and outcome characteristics. Patients with severe forms were not older and did not have more comorbidities than patients with nonsevere forms. At hospital admission, the rates of classical signs of chikungunya, such as fever and peripheral arthralgia, were similar in both groups. Patients with severe forms had significantly less occurrence of headache but increased occurrence of acute cardiac failure; they also had occurrence of organ dysfunction significantly more often than did patients with nonsevere forms (Table 1). As for laboratory abnormalities, patients with severe forms had significantly higher whole leukocyte counts, polymorphonuclear cell counts, and serum lactate dehydrogenase levels at baseline and within the first week after admission (Table 1).
Table 1

Selected characteristics of 110 nonpregnant adult patients with chikungunya virus infection, by severity of disease, University Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, January–November 2014*

Characteristic
Nonsevere, n = 68
Severe, n = 42
p value†
Baseline characteristics
Median age, y (interquartile range)71 (59–80)68 (58–77)0.27
Male sex36 (53)26 (62)0.36
Preexisting comorbid conditions
Immune suppression4 (6)1 (2)0.69
Diabetes mellitus28 (41)16 (38)0.75
Chronic heart disease9 (14)11 (28)0.07
Cerebrovascular disease6 (9)1 (3)0.35
Chronic lung disease1 (2)2 (5)0.66
Chronic liver disease01 (3)0.8
Chronic renal disease5 (8)4 (10)0.95
Cancer5 (8)2 (5)0.92
Charlson index, median (interquartile range)4 (3–5)4 (1–5)0,41
McCabe class 1
50 (77)
24 (62)
0.09
Clinical symptoms, present on admission to hospital
Arthralgia/arthritis49 (82)30 (83)0.84
Headache21 (39)3 (9)0,002
Fever61 (92)35 (83)0.25
Myalgia24 (48)13 (41)0.41
Cardiac manifestations10 (15)28 (67)<0.001
Central nervous system manifestations20 (30)13 (31)<0.001
Respiratory manifestations9 (14)29 (71)<0.001
Hepatic manifestations1 (2)12 (29)<0.001
Renal manifestations
12 (19)
20 (50)
0.001
Organ failures, at any time of the course of the disease
Cardio-circulatory failure022 (52)<0.001
Neurologic failure06 (14)0.006
Respiratory failure021 (50)<0.001
Liver failure09 (21)<0.001
Renal failure
0
15 (36)
<0.001
Laboratory data, median (interquartile range)
Whole leukocytes, day 1, G/L5.80 (4.00–7.00)7.50 (4.90–13.00)0.01
Whole leukocytes, days 2–7, G/L3.00 (2.10–5.40)8.70 (3.20–14.70)<0.001
Polymorphonuclear neutrophils, day 1, G/L4.16 (2.82–5.43)5.59 (3.40–10.94)0.01
Polymorphonuclear neutrophils, days 2–7, G/L1.63 (1.05–5.02)7.13 (2.32–11.82)<0.001
Hemoglobin, day 1, g/dL12.6 (11.3–13.6)12.1 (10.2–13.5)0.25
Hemoglobin, days 2–7, g/dL11.9 (11.3–13.6)8.6 (10.5–11.6)<0.001
Platelets, day 1, G/L178(125–233)147 (107–199)0.13
Platelets, days 2–7, G/L160 (110–200)108 (75–189)0.04
C-reactive protein, day 1, mg/L36 (20–79)43 (16–75)0.57
C-reactive protein, days 2–7, mg/L70 (33–106)94 (37–167)0.24
Lactate dehydrogenase, day 1, IU/L286 (207–354)579 (310–1135)0.001
Lactate dehydrogenase, days 2–7, IU/L363 (248–418)422 (335–1600)0.04
Creatine kinase, day 1, IU/L268 (132–808)395 (237–740)0.36
Creatine kinase, day 2, IU/L973 (163–2826)683 (240–2164)0.85
Aspartate aminotransferase, day 1, IU/L34 (25–48)50 (30–127)0.01
Aspartate aminotransferase, days 2–7, IU/L28 (19–58)64 (33–351)0.2
Alanine aminotransferase, day 1, IU/L20 (15–30)31 (21–57)0.02
Alanine aminotransferase, days 2–7, IU/L28 (19–58)40 (20–234)0.1
Creatinine, day 1, µmol/L95 (78–131)119 (81–182)0.07
Creatinine, days 2–7, µmol/L
101 (81–139)
153 (75–410)
0.09
Outcome
Death1 (2)13 (31)<0.001

*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR.
†p value denotes the comparisons between the 42 patients with severe forms and the 68 patients with nonsevere forms, based on nonparametrical tests.

*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR.
†p value denotes the comparisons between the 42 patients with severe forms and the 68 patients with nonsevere forms, based on nonparametrical tests. Among the 42 patients who had a severe form of the disease, 25 patients had illness consistent with the case definition for severe sepsis and had no other identified cause for this syndrome but CHIKV, according to blood and urine cultures, which had been performed systematically in all these patients. Overall, the background characteristics of these 25 patients were not significantly different from those of the other 85 patients (Tables 1, 2). At admission to hospital, these 25 patients had significantly higher occurrence of cardiac, respiratory, and renal manifestations and had significantly higher leukocyte counts and levels of serum lactate dehydrogenase, aspartate aminotransferase, and creatinine, which are clinical and laboratory indicators of sepsis, than did patients without severe sepsis or septic shock (Table 2). In addition, their mortality rate was significantly higher than that in patients without severe sepsis or septic shock (48% vs. 3%, p<0.001).
Table 2

Selected characteristics of 110 nonpregnant adult patients with chikungunya virus infection, by presence or absence of sepsis or septic shock, University Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, January–November 2014*

CharacteristicSevere sepsis or septic shock, n = 25No severe sepsis or septic shock, n = 85p value†
Baseline characteristics
Median age, y (interquartile range)70 (59–77)70 (59–78)0.966
Male sex17 (68)45 (53)0.252
Preexisting comorbid conditions
Immune suppression1 (4)4 (5)1
Diabetes mellitus10 (40)34 (40)1
Chronic heart disease6 (26)14 (17)0.374
Cerebrovascular disease1 (4)6 (8)1
Chronic lung disease2 (9)1 (1)0.124
Chronic liver disease1 (4)0 (0)0.223
Chronic renal disease3 (13)6 (8)0.414
Cancer1 (4)6 (7)1
Charlson index, median (interquartile range)4 (3–5)4 (2–5)0.579
McCabe class 1
9 (39)
21 (26)
0.296
Clinical symptoms, present on admission to hospital
Arthralgia/arthritis19 (91)60 (80)0.347
Headache3 (17)21 (30)0.376
Fever21 (84)75 (90)0.467
Myalgia8 (44)29 (45)1
Cardiac manifestations20 (80)18 (22)<0.001
Central nervous system manifestations8 (32)25 (30)1
Respiratory manifestations18 (72)20 (24)<0.001
Hepatic manifestations7 (28)6 (8)0.012
Renal manifestations
17 (71)
15 (19)
<0.001
Organ failures, at any time of the course of the disease
Cardio-circulatory failure17 (68)5 (6)<0.001
Neurologic failure3 (12)3 (4)0.129
Respiratory failure14 (56)7 (8)<0.001
Liver failure6 (24)3 (4)0.004
Renal failure
13 (52)
2 (2)
<0.001
Laboratory data, median (interquartile range)
Whole leukocytes, day 1, G/L8.10 (6.10–13.10)5.80 (4.10–7.10)0.004
Whole leukocytes, days 2–7, G/L10.70 (3.40–15.00)3.05 (2.35–7.00)<0.001
Polymorphonuclear neutrophils, day 1, G/L5.96 (4.48–11.02)4.30 (2.82–5.91)0.01
Polymorphonuclear neutrophils, days 2–7, G/L8.73 (2.55–12.02)1.80 (1.09–5.86)<0.001
Hemoglobin, day 1, g/dL12.1 (10.6–13.5)12.5 (11.2–13.5)0.796
Hemoglobin, days 2–7, g/dL10.6 (7.9–11.7)11.7 (10.3–12.9)0.013
Platelets, day 1, G/L139 (106–192)176 (123–233)0.063
Platelets, days 2–7, G/L104 (59–189)149 (108–200)0.03
C-reactive protein, day 1, mg/L46 (20–75)40 (20–79)0.856
C-reactive protein, days 2–7, mg/L92 (41–204)70 (33–106)0.119
Lactate dehydrogenase, day 1, IU/L606 (288–946)310 (226–401)0.007
Lactate dehydrogenase, days 2–7, IU/L422 (346–1600)363 (266–422)0.05
Creatine kinase, day 1, IU/L653 (304–1394)264 (140–639)0.08
Creatine kinase, day 2, IU/L911 (357–3932)727 (163–2642)0.283
Aspartate aminotransferase, day 1, IU/L60 (39–127)33 (24–48)0.001
Aspartate aminotransferase, days 2–7, IU/L125 (36–626)54 (35–104)0.044
Alanine aminotransferase, day 1, IU/L33 (24–57)20 (15–31)0.02
Alanine aminotransferase, days 2–7, IU/L56 (28–499)30 (19–61)0.055
Creatinine, day 1, µmol/L157 (114–343)96 (77–134)0.008
Creatinine, days 2–7, µmol/L
226 (123–570)
101 (76–141)
0.002
Outcome
Death12 (48)2 (3)<0.001

*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR.
†p value denotes the comparisons between the 25 patients with severe sepsis or septic shock and the 85 patients with no severe sepsis or septic shock, based on nonparametrical tests.

*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR.
†p value denotes the comparisons between the 25 patients with severe sepsis or septic shock and the 85 patients with no severe sepsis or septic shock, based on nonparametrical tests. The following case report describes one of the 25 patients with severe sepsis or septic shock. The patient died of septic shock, which had no other identified cause but CHIKV infection. An 85-year-old man with no prior medical history except treated hypertension developed an acute influenza-like syndrome. On day 2 of illness, a common form of CHIKV infection was diagnosed by his general practitioner, and the patient received treatment for his symptoms. On day 4, he was referred to a hospital emergency department because of persistent high-grade fever. His hemodynamic condition was normal, and the diagnosis of CHIKV infection was maintained; however, because of elevated levels of whole leukocytes (total 40 G/L), polymorphonuclear neutrophils (37.5 G/L), and serum C-reactive protein (170 mg/L), blood and urine samples were collected for culture, and treatment with ceftriaxone was started. Approximately 12 hours after admission to the emergency department, the patient experienced onset of septic shock and died within 4 hours. All blood and urine cultures were negative for CHIV. A PCR test for leptospirosis also was negative. A CHIKV-positive RT-PCR test result was the only positive diagnostic test result obtained for this patient.

Conclusions

Although chikungunya usually has a mild course, severe life-threatening complications can develop during the acute phase of the disease (,). Previous studies indicate that the disease can be complicated by severe multiple organ failure and lead to death (,). Very recently, the first cases of severe sepsis and septic shock that could be attributed to CHIKV infection were reported (,). In some of these cases, acral skin necrosis was observed (). The replication of viruses, especially of the family Herpetoviridae, has been shown to occur frequently during the course of septic shock syndromes of bacterial origin, not only as a stress-induced reactivation but also as a superinfection causing additional morbidity (). By contrast, cases of virus-triggered septic shock have been reported only rarely (), although a recent cross-sectional study of septic shock syndromes in a pediatric population suggested that viruses might be the only etiology in up to 10% of cases (). On the other hand, genuine acute severe viral infections might be complicated with a bacterial septic shock, which is well known to occur in cases of influenza but has also been reported in cases of arboviral diseases, such as dengue fever (). In our study, none of the 25 patients who had a positive CHIKV RT-PCR test result and a severe sepsis or septic shock syndrome early in the course of chikungunya had another organism identified as a potential cause of sepsis. This finding strongly suggests that CHIKV can, in rare cases, cause severe sepsis and septic shock syndromes, an observation that had not been reported until very recently. Additional studies are needed to identify any background characteristics that might be associated with the onset of severe sepsis or septic shock.
  14 in total

1.  Etiologies of septic shock in a pediatric emergency department population.

Authors:  Nakia N Gaines; Binita Patel; Eric A Williams; Andrea T Cruz
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

Review 2.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

3.  Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013.

Authors:  S Cassadou; S Boucau; M Petit-Sinturel; P Huc; I Leparc-Goffart; M Ledrans
Journal:  Euro Surveill       Date:  2014-04-03

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Nasal Skin Necrosis: An Unexpected New Finding in Severe Chikungunya Fever.

Authors:  Jaime R Torres; Leopoldo G Córdova; Víctor Saravia; Joanne Arvelaez; Julio S Castro
Journal:  Clin Infect Dis       Date:  2015-09-29       Impact factor: 9.079

6.  Chikungunya virus-associated death in Malaysia.

Authors:  I C Sam; A Kamarulzaman; G S Y Ong; R S Veriah; S Ponnampalavanar; Y F Chan; S AbuBakar
Journal:  Trop Biomed       Date:  2010-08       Impact factor: 0.623

7.  Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic.

Authors:  Alladi Mohan; D H N Kiran; I Chiranjeevi Manohar; D Prabath Kumar
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

8.  Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion.

Authors:  A Economopoulou; M Dominguez; B Helynck; D Sissoko; O Wichmann; P Quenel; P Germonneau; I Quatresous
Journal:  Epidemiol Infect       Date:  2008-08-11       Impact factor: 2.451

Review 9.  Atypical manifestations of chikungunya infection.

Authors:  Senaka Rajapakse; Chathuraka Rodrigo; Anoja Rajapakse
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-08-27       Impact factor: 2.184

10.  Chikungunya fever: Atypical and lethal cases in the Western hemisphere: A Venezuelan experience.

Authors:  Jaime R Torres; Julio S Castro; Libsen Rodríguez; Víctor Saravia; Joanne Arvelaez; Antonio Ríos-Fabra; María A Longhi; Melania Marcano
Journal:  IDCases       Date:  2014-12-18
View more
  25 in total

1.  Excess deaths associated with the 2014 chikungunya epidemic in Jamaica.

Authors:  André Ricardo Ribas Freitas; Patrick Gérardin; Luiza Kassar; Maria Rita Donalisio
Journal:  Pathog Glob Health       Date:  2019-02-04       Impact factor: 2.894

2.  Guillain-Barré Syndrome and Chikungunya: Description of All Cases Diagnosed during the 2014 Outbreak in the French West Indies.

Authors:  Stephanie Balavoine; Mathilde Pircher; Bruno Hoen; Cecile Herrmann-Storck; Fatiha Najioullah; Benjamin Madeux; Aissatou Signate; Ruddy Valentino; Annie Lannuzel; Magali Saint Louis; Sylvie Cassadou; André Cabié; Kinda Schepers
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

3.  Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana.

Authors:  Timothée Bonifay; Jean-François Lienne; Cécile Bagoée; Florin Santa; Guillaume Vesin; Gaëlle Walter; Mathieu Nacher; Nathalie Vaserman; Félix Djossou; Loïc Epelboin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-17       Impact factor: 5.103

4.  Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells.

Authors:  Mariana Ruiz Silva; Heidi van der Ende-Metselaar; H Lie Mulder; Jolanda M Smit; Izabela A Rodenhuis-Zybert
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

5.  Severe Chikungunya infection in Northern Mozambique: a case report.

Authors:  Mussa Manuel Aly; Sadia Ali; Argentina Felisbela Muianga; Vanessa Monteiro; Jorge Galano Gallego; Jacqueline Weyer; Kerstin I Falk; Janusz Tadeusz Paweska; Julie Cliff; Eduardo Samo Gudo
Journal:  BMC Res Notes       Date:  2017-02-08

6.  Prognostic factors of inhospital death in elderly patients: a time-to-event analysis of a cohort study in Martinique (French West Indies).

Authors:  Lidvine Godaert; Seendy Bartholet; Fréderique Dorléans; Fatiha Najioullah; Sebastien Colas; Jean-Luc Fanon; André Cabié; Raymond Césaire; Moustapha Dramé
Journal:  BMJ Open       Date:  2018-01-23       Impact factor: 2.692

7.  Severity of acute Zika virus infection: A prospective emergency room surveillance study during the 2015-2016 outbreak in Suriname.

Authors:  Pieter Vroon; Jimmy Roosblad; Fauzia Poese; Jan Wilschut; John Codrington; Stephen Vreden; Rens Zonneveld
Journal:  IDCases       Date:  2017-10-23

Review 8.  The MAVS Immune Recognition Pathway in Viral Infection and Sepsis.

Authors:  Arjun Sharma; Konstantinos Kontodimas; Markus Bosmann
Journal:  Antioxid Redox Signal       Date:  2021-09-28       Impact factor: 8.401

Review 9.  Rediscovering the chikungunya virus

Authors:  Eliana Patricia Calvo; Edwin Darío Archila; Lady López; Jaime Eduardo Castellanos
Journal:  Biomedica       Date:  2021-06-29       Impact factor: 0.935

Review 10.  Contribution of Research in the West Indies and Northeast Amazonia to Knowledge of the 2014-2015 Chikungunya Epidemic in the Americas.

Authors:  Timothee Bonifay; Lidvine Godaert; Yanouk Epelboin; Dominique Rousset; Maylis Douine; Hélène Hilderal; Cyril Clavel; Sylvie Abel; Fatiha Najioullah; Laurence Fagour; Margarete do Socorro Mendonça Gomes; Marcus Lacerda; Raymond Cézaire; Narcisse Elenga; Moustapha Dramé; Bruno Hoen; André Cabié; Félix Djossou; Loïc Epelboin
Journal:  Curr Trop Med Rep       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.